Live
Endpoints NewsDid Eli Lilly just strike another gold mine?Endpoints NewsWhat’s familiar in health tech’s Q1 funding totalsEndpoints NewsStudy suggests $35 monthly insulin cap has increased patient accessPromega BlogNew Study Suggests Cancer Research Has an Age ProblemEndpoints NewsWhite House adds AbbVie's Humira to TrumpRx alongside cheaper biosimilarsBioPharma DiveTerns rebuffed a higher bid before selling to MerckFierceBiotechLilly pays AC Immune $12.5M to expand Alzheimer’s collab as asset draws closer to clinicFierceBiotechLongtime Hologic CEO Steve MacMillan to retire as $18.3B deal closesFierceBiotechOwlet CEO exits suddenly, co-founder returns to the nestFierceBiotechE2 lands $80M series C for next gen thrombectomy treatmentFierceBiotechCRO Fortrea launches AI-powered solution to improve trial efficiencyBioWorldAppointments and advancements for April 7, 2026
BioWorld Feb 3, 2026

Amgen quits Kyowa Kirin deal, returns rocatinlimab

Amgen quits Kyowa Kirin deal, returns rocatinlimab

Original
Body unavailable. Use the original source.

Directory

59 All